PATENT CLAIM ANALYSIS

Application Number: 15897847
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["424", "136100"]

Abstract:
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-TNF-α antibody or antigen-binding fragment thereof and at least one anti-IL-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a DNL® complex. The anti-TNF-α or anti-IL-6 antibodies may comprise specific CDR sequences disclosed herein. The compositions and methods are of use to treat autoimmune disease, immune system dysfunction or inflammatory disease, as disclosed herein.

Claim (Index 1):
A murine, chimeric, humanized or human anti-TNF-\u03b1 antibody or antigen-binding fragment thereof comprising the heavy chain CDR sequences CDR1 (GFWN, SEQ ID NO:113), CDR2 (YISYSGRTYYNPSLKS, SEQ ID NO:114) and CDR3 (DANYVLDY, SEQ ID NO:115) and the light chain CDR sequences CDR1 (KSSQSLLNSSTQKNYLA, SEQ ID NO:116), CDR2 (FASARES, SEQ ID NO:117) and CDR3 (QQHYRTPFT, SEQ ID NO:118).

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.69388
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14525690', '15620126', '15487747', '15005596', '15604153']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.746406419771969
- 35 USC 102 Novelty (BERT): 0.647665172431507
- Combined Prediction Score: 0.7365322950379228
- Mean Citation Score: 510.821424
- Max Citation Score: 641.9966
- Similarity Product: 574.7429934184313

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test